147 million partnership to supercharge vaccine development

first_imgReviewed by James Ives, M.Psych. (Editor)Jan 16 2019Vaccines to stop the world’s next epidemic could be developed in record time under a $14.7 million partnership using technology developed at The University of Queensland.The Coalition for Epidemic Preparedness Innovations (CEPI) has funded a research consortium to develop a rapid response pipeline to develop and test new vaccines in as little as 16 weeks.The Australia Government has been an early supporter of CEPI by providing a previous contribution of $2 million, and UQ and CEPI are pleased to see a further contribution today of $4.5 million.UQ’s Professor Paul Young and Dr Keith Chappell are leading the project, which has the potential to save millions of lives by targeting existing and new pathogens.”The World Health Organization’s Blueprint list of priority diseases recognises that new epidemics can arise from known and unknown viruses – the latter referred to as ‘Disease X’,” Professor Young said.Related StoriesScripps CHAVD wins $129 million NIH grant to advance new HIV vaccine approachUM scientists receive $3.3 million NIH contract to develop opioid addiction vaccineMore effective flu vaccine begins clinical trials across the U.S.”These new and emerging pathogens have the potential to reach global epidemic levels.”Dr Chappell said the project was ambitious, as more conventional approaches could take years or even decades.”We aim to be able to manufacture more than 200,000 doses of a new vaccine, demonstrate safety and the likelihood of efficacy, and be ready for field deployment in as little as six months,” he said.Professor Young, Dr Chappell and Dr Daniel Watterson have patented ‘molecular clamp’ technology that provides stability to the viral proteins that are the primary target of our immune defence.”The technology has been designed as a platform approach to generate vaccines against a range of human and animal viruses,” Professor Young said.”We’ve had some extremely promising results so far from trials targeting viruses such as influenza, Ebola, Nipah and MERS coronavirus.”Dr Watterson said the collaboration would act as an insurance policy against deadly outbreaks caused by the emergence of viral epidemics or pandemics.”By rapidly creating vaccines to these new threats, we’ll be able to quickly limit the spread of disease and diffuse potentially catastrophic situations.”Molecular clamp technology has the potential to address some of today’s most devastating diseases and to fundamentally change how we protect ourselves from common diseases.”Source: https://www.uq.edu.au/news/article/2019/01/partnership-supercharge-vaccine-productionlast_img

Leave a Reply

Your email address will not be published. Required fields are marked *